Europe Organoids Services Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis

Description

List of Tables

The Europe organoids services market is projected to grow significantly, reaching approximately US$ 5,016.03 million by 2031, up from US$ 1,233.51 million in 2024. This growth represents a compound annual growth rate (CAGR) of 22.2% from 2024 to 2031.

Executive Summary and Market Analysis

The market for organoid services in Europe is divided into several key regions, including Germany, France, the UK, Spain, Italy, and the Rest of Europe. The growth in this market is driven by several factors, including the increasing demand for tissue engineering and organ transplantation, the rising use of organoids in disease modeling, gene mutation studies, and tumor modeling, as well as a surge in research and development focused on organoids. Additionally, enhanced funding and investments from both public and private sectors are expected to create substantial opportunities in the market in the near future.

Market Segmentation Analysis

The Europe organoids services market can be segmented based on type, application, and source:

By Type: The market is categorized into various organ types, including intestine, liver, stomach, pancreas, lung, brain, kidney, and others. In 2024, the intestine segment is anticipated to hold the largest market share.
By Application: The applications of organoids are segmented into developmental biology disease, pathology of infectious diseases, regenerative medicine, drug toxicity and efficacy testing, drug discovery and personalized medicine, among others. The developmental biology disease segment is expected to dominate the market in 2024.
By Source: The market is also segmented by the source of organoids, which includes pluripotent stem cells and organ-specific adult stem cells. The pluripotent stem cells segment is projected to have a larger market share in 2024.

Market Outlook

The increasing demand for personalized medicine in Europe is a significant factor influencing the advancement and application of organoid technologies, particularly in oncology and genetic disorders. A notable collaboration between King's College London and GSK exemplifies this trend, where researchers are developing patient-derived lung cancer organoids to predict relapse and identify effective treatment combinations. These organoids are designed to reflect the unique genetic mutations found in each patient's cancer, facilitating tailored therapy selection. Furthermore, the European Medicines Agency (EMA) has recognized the importance of organoid technology in precision medicine, supporting innovative methods like organoids through its adaptive pathways initiative to expedite the approval of new therapies, thus bridging the gap between research and clinical application.

Country Insights

The Europe organoids services market includes key countries such as the UK, France, Germany, Spain, Italy, and the Rest of Europe. Germany is expected to hold the largest market share in 2024.

The demand for organoid services in Germany is on the rise, driven by advancements in tissue engineering and organ transplantation, along with ongoing organoid research. The country's robust research sector is leading to the emergence of new organoid generation methods, enhancing their role in human disease modeling and opening new research avenues. Germany's biotechnology industry shows significant growth potential, supported by the high quality of its products. Numerous companies specializing in organoid services operate within the country, such as the Max Delbruck Center in Berlin, which provides platform services for organoid derivation and characterization.

Company Profiles

Key players in the Europe organoids services market include CUSABIO TECHNOLOGY LLC, Cyprio, Eurofins Scientific SE, HUB Organoids B.V. (Hubrecht Organoid Technology), InnoSer, InSphero, LABTOO, Molecular Devices, LLC, Oncodesign Services, and Sino Biological Inc., among others. These companies are employing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their offerings and increase their market presence.

Product Code: BMIRE00032024

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:

4. Europe Organoids Services Market Landscape

4.1 PEST Analysis

5. Europe Organoids Services Market - Key Market Dynamics

5.1 Europe Organoids Services Market - Key Market Dynamics
5.2 Market Drivers
- 5.2.1 Increasing Demand for Innovative Drug Screening Services
- 5.2.2 Surge in Popularity of Personalized Drugs
5.3 Market Restraints
- 5.3.1 Dearth of Skilled Professionals
5.4 Market Opportunities
- 5.4.1 Increasing Key Developments
5.5 Future Trends
- 5.5.1 Integration of Artificial Intelligence
5.6 Impact of Drivers and Restraints:

6. Europe Organoids Services Market - Analysis

6.1 Europe Organoids Services Market Revenue (US$ Million), 2021-2031
6.2 Europe Organoids Services Market Forecast Analysis

7. Europe Organoids Services Market Analysis - by Type

7.1 Intestine
- 7.1.1 Overview
- 7.1.2 Intestine: Europe Organoids Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.2 Liver
- 7.2.1 Overview
- 7.2.2 Liver: Europe Organoids Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.3 Stomach
- 7.3.1 Overview
- 7.3.2 Stomach: Europe Organoids Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.4 Pancreas
- 7.4.1 Overview
- 7.4.2 Pancreas: Europe Organoids Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.5 Lung
- 7.5.1 Overview
- 7.5.2 Lung: Europe Organoids Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.6 Brain
- 7.6.1 Overview
- 7.6.2 Brain: Europe Organoids Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.7 Kidney
- 7.7.1 Overview
- 7.7.2 Kidney: Europe Organoids Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.8 Others
- 7.8.1 Overview
- 7.8.2 Others: Europe Organoids Services Market - Revenue and Forecast, 2021-2031 (US$ Million)

8. Europe Organoids Services Market Analysis - by Application

8.1 Developmental Biology Disease
- 8.1.1 Overview
- 8.1.2 Developmental Biology Disease: Europe Organoids Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.2 Pathology of Infectious Disease
- 8.2.1 Overview
- 8.2.2 Pathology of Infectious Disease: Europe Organoids Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.3 Regenerative Medicine
- 8.3.1 Overview
- 8.3.2 Regenerative Medicine: Europe Organoids Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.4 Drug Toxicity and Efficacy Testing
- 8.4.1 Overview
- 8.4.2 Drug Toxicity and Efficacy Testing: Europe Organoids Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.5 Drug Discovery and Personalized Medicine
- 8.5.1 Overview
- 8.5.2 Drug Discovery and Personalized Medicine: Europe Organoids Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.6 Others
- 8.6.1 Overview
- 8.6.2 Others: Europe Organoids Services Market - Revenue and Forecast, 2021-2031 (US$ Million)

9. Europe Organoids Services Market Analysis - by Source

9.1 Pluripotent Stem Cells
- 9.1.1 Overview
- 9.1.2 Pluripotent Stem Cells: Europe Organoids Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
9.2 Organ Specific Adult Stem Cell
- 9.2.1 Overview
- 9.2.2 Organ Specific Adult Stem Cell: Europe Organoids Services Market - Revenue and Forecast, 2021-2031 (US$ Million)

10. Europe Organoids Services Market - Country Analysis

10.1 Europe
- 10.1.1 Europe Organoids Services Market - Revenue and Forecast Analysis - by Country
  - 10.1.1.1 Europe Organoids Services Market - Revenue and Forecast Analysis - by Country
  - 10.1.1.2 Germany: Europe Organoids Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.1.2.1 Germany: Europe Organoids Services Market Share - by Type
    - 10.1.1.2.2 Germany: Europe Organoids Services Market Share - by Application
    - 10.1.1.2.3 Germany: Europe Organoids Services Market Share - by Source
  - 10.1.1.3 United Kingdom: Europe Organoids Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.1.3.1 United Kingdom: Europe Organoids Services Market Share - by Type
    - 10.1.1.3.2 United Kingdom: Europe Organoids Services Market Share - by Application
    - 10.1.1.3.3 United Kingdom: Europe Organoids Services Market Share - by Source
  - 10.1.1.4 France: Europe Organoids Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.1.4.1 France: Europe Organoids Services Market Share - by Type
    - 10.1.1.4.2 France: Europe Organoids Services Market Share - by Application
    - 10.1.1.4.3 France: Europe Organoids Services Market Share - by Source
  - 10.1.1.5 Italy: Europe Organoids Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.1.5.1 Italy: Europe Organoids Services Market Share - by Type
    - 10.1.1.5.2 Italy: Europe Organoids Services Market Share - by Application
    - 10.1.1.5.3 Italy: Europe Organoids Services Market Share - by Source
  - 10.1.1.6 Spain: Europe Organoids Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.1.6.1 Spain: Europe Organoids Services Market Share - by Type
    - 10.1.1.6.2 Spain: Europe Organoids Services Market Share - by Application
    - 10.1.1.6.3 Spain: Europe Organoids Services Market Share - by Source
  - 10.1.1.7 Rest of Europe: Europe Organoids Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.1.7.1 Rest of Europe: Europe Organoids Services Market Share - by Type
    - 10.1.1.7.2 Rest of Europe: Europe Organoids Services Market Share - by Application
    - 10.1.1.7.3 Rest of Europe: Europe Organoids Services Market Share - by Source

11. Industry Landscape

11.1 Overview
11.2 Growth Strategies in Organoids Services Market
11.3 Organic Growth Strategies
- 11.3.1 Overview
11.4 Inorganic Growth Strategies
- 11.4.1 Overview

12. Company Profiles

12.1 Sino Biological Inc.
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Eurofins Scientific SE
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Molecular Devices, LLC.
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 InSphero
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Cyprio
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 InnoSer
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 LABTOO
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 CUSABIO TECHNOLOGY LLC
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 Oncodesign Services
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
12.10 HUB Organoids B.V. (Hubrecht Organoid Technology)
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments

13. Appendix

13.1 About The Insight Partners
13.2 Glossary of Terms